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Abstract: High-frequency ultrasound (8–14 MHz) is routinely used to display cutaneous 
melanomas. Maximum thickness measurement (Breslow index) has been shown to be well 
correlated to histologic findings for lesions of more than 0.75 mm. Some morphological 
criteria (strong delineation, hypoechoic texture, homogeneity) have been reported to help 
differentiate between malignant and benign pigmented blue lesions, but remain insufficient. 
Vascular ultrasound analysis using Doppler mode provides additional information and showed   
good specificity for malignancy (90%–100%), but variable sensitivity (34%–100%). Recent 
advances  in  ultrasound  imaging  allow  functional  evaluation.  Likewise,  dynamic  contrast-
enhanced ultrasound using contrast medium injection and specific perfusion and quantification 
software showed promising results in clinical and preclinical trials for early prediction of tumor 
response to target treatments.
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Introduction
Melanoma imaging has benefited from significant advances in ultrasound imaging. 
Indeed, since the 1990s, because of its accessibility, low cost, and the shallowness of 
lesions, this technique has rapidly become established as an essential continuum to 
the clinical examination. Today, advances in high-frequency probes allow accurate 
detection, characterization, and measurement of lesions.
Functional imaging has recently become an important issue in oncology for 
evaluation of new targeted therapies and antiangiogenic treatments allowing very 
early assessment of treatment effectiveness. In particular, ultrasound with injection 
of contrast medium could play an important role alongside other functional imaging 
modalities, such as positron emission tomography, computed tomography, or magnetic 
resonance imaging. It is yet to be established which melanomas may be susceptible 
to treatment with a combination of antiangiogenic agents and chemotherapy, and cur-
rent treatment monitoring is in need of a reliable functional imaging tool. This paper 
reviews the role of different ultrasound modalities (from morphologic to vascular 
assessment) in initial management of primary melanoma and outlines the development 
and importance of new functional ultrasound modalities for monitoring antiangiogenic 
or antivascular treatments.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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Morphologic analysis  
and sonometry: Breslow index
It is now recognized that high frequency ultrasound is 
superior to clinical examination alone for the detection 
and measurement of superficial lesions. In skin melanoma, 
the maximum thickness (Breslow index) is considered 
as the main prognostic factor related to metastatic potential. 
The Breslow index determines the margins of resection of the 
primary tumor and the sentinel node biopsy procedure.
The accuracy of measurement of thickness depends on the 
axial resolution of the ultrasound system. Axial resolution is 
basically defined as the shortest distance between two targets 
on the firing axis of the probe that can be separated on the 
image. The shortest distance (δ) is approximately equivalent 
to the length of the ultrasonic wave (λ), which is inversely 
proportional to the frequency of the probe (F): δ ∼ λ ∼ (1/F). 
Therefore, the higher the frequency of the probe, the better the 
resolution and the smaller the measured distance. On the other 
hand, the wavelength is also dependent on ultrasound velocity 
(c) in the propagation medium (λ = c/F). Weichenthal et al 
showed in a small melanoma sample that ultrasound veloci-
ties and therefore the measured distances varied from one 
tumor to another and within the same tumor, but the relative 
amount of variation seemed to be low.1
Since the early 1980s, several in vivo and in vitro 
studies2–7 have shown that ultrasound using high-frequency 
probes (7–20 mHz) produced thickness measurements 
superimposable on histologic measurements, with differ-
ences of less than 0.2 mm8 and correlation coefficients $0.95 
because of a high resolution rate (precision 0.01 mm).5,9 
Therefore, correlation between sonometry and histometry 
is high but not ideal, in particular for lesions less than 
1 mm in thickness, and many authors have suggested that 
the accuracy of ultrasound measurement would be improved 
by using probes of very high frequency (.20 mHz). Some 
authors have proposed use of 100 mHz ultrasound for skin 
lesions less than 1 mm thickness.10 A recent study by Guitera 
et al enhanced the use of frequency probes of 75 mHz, and 
their results showed that in situ melanoma tended to have a 
poor correlation with histometry in contrast with invasive 
melanoma.11 Generally, sonometry is reported to be highly 
correlated with histometry for lesions greater than 0.75 mm 
in thickness.12
Nevertheless, because of its noninvasiveness and accu-
rate measurement, high frequency ultrasound remains an 
effective preoperative imaging tool to adjust the operative 
strategy at the outset according to the index and then avoiding 
reoperations that had to be performed in 30% of cases when 
Breslow index was measured subsequently at surgery.13–15
Morphologic analysis in gray  
scale ultrasound: malignant  
or benign lesion
Assessment and management of pigmented lesions of the skin 
(melanoma, basal/squamous cell carcinoma, nevus, keratosis, 
lentigo, capillary thrombosis, histiocytofibroma) are based on 
clinical evaluation, but differentiation between benignancy 
and malignancy is often problematic. In a recent study 
including 39 blue skin lesions, high frequency ultrasonogra-
phy (20 mHz) was reported to be more specific than clinical 
examination and dermoscopy for differentiating melanoma 
from blue nevi (specificity 94%, 77%, and 74%, respectively) 
but clinical diagnosis was more sensitive ( 77.9% versus 70% 
for dermoscopy and 70.8% for sonography).16
In gray scale mode, the image formation corresponds 
with a two-dimensional representation of the ultrasound 
signal arising from several acoustic phenomena, ie, reflection 
(allowing visualization of an interface between two media 
with different acoustic properties), diffusion (determining 
signal amplitude and intensity and then coded in gray scale), 
and absorption of the ultrasound beam through the tissue.
Depending on the brightness of each pixel on the video 
screen, an image is constructed, and on ultrasound imaging 
the majority of skin lesions appear as hypoechoic cutaneous 
or subcutaneous thickening. Sonographic features that can 
assist in the differential diagnosis between benign pigmented 
lesions and melanoma have been widely discussed in 
literature, ie, location, echogenicity, homogeneity, shape, 
margins, increased posterior echogenicity, and acoustic 
shadowing. Melanomas have been generally described as 
more homogeneous with well defined margins compared with 
other lesions, with a sensitivity of 100% for these criteria in 
a series of 114 lesions.7
Harland et al studied quantitative acoustic parameters 
provided from high resolution ultrasound in melanoma 
and benign pigmented lesions by using objective measures 
of acoustic shadowing, intralesional sound reflection, and 
surface sound reflectance characteristics. They confirmed that 
significant acoustic differences arise between melanoma and 
benign pigmented lesions, ie, melanomas were reported to be 
less attenuating than benign lesions and, furthermore, they 
showed that melanomas were more homogeneous compared 
with seborrheic keratoses (specificity of 79% and sensitivity 
of 100%).6,17Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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Nevertheless, these morphologic criteria alone are 
insufficient in lesion characterization and assessment. 
Some authors have now focused on tumor microvasculature 
analysis.
Vascular analysis: color  
and power Doppler 
Since work by Srisvastava et al18 was published in 
1989, several studies have focused on analysis of tumor 
microvasculature. It has been shown in animal models that 
Doppler mode (color or power Doppler) allows microvessel 
detection with a threshold of 100 µm. A high correlation with 
histologic and immunohistochemical specimens in terms of 
vascular density has been reported.8,13
Detection of microvessels in a skin lesion increases the 
conspicuity for malignancy, but reports in the literature are 
still variable in that microvessel detection has shown a good 
specificity for malignancy (90%–100%) but sensitivity has 
been in the 34%–100% range.19 These variations could be 
related to the natural history of angiogenesis in tumors and also 
to the advances in ultrasound. Srisvastava et al showed in a 
small series of 21 patients that neovascularization is detectable 
by pulsed Doppler until a lesion thickness of 0.8 mm.18 
In a most recent series using color   Doppler in 67 and 107 
patients,7,20 the thickness threshold for   vessel detection was 
2 mm; in these patients, 87% of skin melanomas more than 
2 mm in thickness were perfused and 95% of melanoma less 
than 2 mm in thickness were not. Thus, the authors concluded 
that the conspicuity for malignancy was strong when vessels 
were detected in a hypoechoic lesion more than 2 mm in thick-
ness. Conversely, the absence of vessels in a lesion of less than 
2 mm does not enable benignancy to be confirmed.
Moreover, vascular density, as observed by Doppler 
ultrasound, has been shown to be correlated with metastatic 
potential.21,22 Hence, in a study involving 107 lesions with a 
follow-up of five years, Breslow index and vascular density as 
determined by color Doppler were shown to be independently 
and significantly correlated with metastatic dissemination.23 
Therefore, neovascularization is a prognostic factor for 
metastasis equivalent to the Breslow index. The assessment 
of tumor perfusion is therefore becoming an issue in the 
management of these patients.
Functional assessment
early assessment of treatment response
The emergence of new targeted therapies in oncology led 
to reconsideration of assessment and treatment through 
functional evaluation rather than morphologic evaluation 
which does not detect early biologic tumor changes.
It is now recognized that morphologic criteria alone 
cannot determine rapidly if treatment is effective or not.24 It 
has yet to be established which melanomas may be susceptible 
to treatments with antiangiogenic agents in combination with 
chemotherapy.25 In fact, agents that neutralize the biologic 
activity of human vascular endothelial growth factor may be 
useful in melanoma management by inducing a decrease in 
angiogenesis, followed by hypoxia and cell death.26
Animal studies in the late 1990s27,28 and Phase I and II 
human studies in the early 2000s29 showed that a decrease 
in tumor vessels, as determined by Doppler ultrasound, 
reflected the effectiveness of targeted treatments before 
any reduction in tumor volume was detected. Similarly, 
in 2003, a study performed in 18 patients with in transit 
melanoma metastases treated by isolated limb perfusion 
(using tumor necrosis factor alpha) showed that an early 
decrease in vascularization, as determined by ultrasound 
color Doppler, predicted a complete response before any 
morphologic changes could be detected.30 Furthermore, in 
skin melanoma, Grünhagen and Eggermont hypothesized 
that initial vascular density should be predictive of tumor 
response after isolated limb perfusion because the more 
vascularized tumors should respond better to treatment due 
to greater infiltration by chemotherapy.31
Contrast-enhanced ultrasound
Since 1999, the use of ultrasound contrast agents has made 
great strides in evaluating tumor microvasculature. The 
contribution of dynamic contrast-enhanced ultrasound in 
antiangiogenic treatment assessment has been widely dis-
cussed by Lassau et al,24,32 underscoring the usefulness of 
this method as a functional modality for monitoring targeted 
treatments.
Injection of contrast medium displays functional 
information of tumor perfusion. Contrast media used in 
ultrasound are similar to encapsulated gas microbubbles. 
These microbubbles have a strictly intravascular distribution 
and the use of specific software displays more accurate 
and sensitive information with fewer artifacts (decrease of 
blooming effect) than color or power Doppler. The acoustic 
properties of the microbubbles increase the signal-to-noise 
ratio and sensitivity in microvessel detection. Since the 
arrival of first-generation contrast media (Levovist®), the 
threshold in microvessel detection decreased from 100 to 
40 µm when compared with power Doppler mode.33Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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Dynamic contrast-enhanced ultrasound has been used in 
clinical studies to assess tumor response to antiangiogenic 
or antivascular therapies. In a study involving patients 
treated with isolated limb perfusion for sarcoma, functional 
  evaluation (dynamic contrast-enhanced ultrasound performed 
at days 1, 7, and 14, and at one month and two months by 
Levovist injection) showed that perfusion changes (in terms 
of vessel count) were able to predict early (from day 1) 
response in 49 patients.34 Sensitivity, specificity, positive 
predictive value (PPV), and the negative predictive value 
(NPV) were 89%, 100%, 100%, and 90%, respectively. 
Thus, this imaging modality has been proposed by surgeons 
to possibly adjust the timetable for surgery.35
Levovist, which in the early 2000s was the first ultra-
sound contrast medium used in France, displayed destructive 
imaging. This method requires significant acoustic power 
which leads to the destruction of microbubbles. Since 2003, 
the arrival of second-generation contrast media, eg, SonoVue® 
enables a new approach to imaging which is no longer a 
destructive mode but a real-time mode using a low mechani-
cal index while preserving microbubbles. This approach has 
been made possible as a result of recent technologic develop-
ments that combine the advantages of harmonic imaging (in 
terms of resolution) with those of specific software (specific 
processing of microbubble signals). This new software can 
recover the high amplitude signal emitted by microbubbles 
in spite of nonvascular signals. The duration of the signal 
depends on the half-life of the microbubbles in the circula-
tion. Real-time imaging allows accurate assessment of tumor 
Figure  1  In  left  window,  dynamic  contrast-enhanced  ultrasound  evaluation  of 
superficial skin melanoma after injection of contrast medium (SonoVue®) and using 
perfusion  software  (vascular  Recognition  Imaging,  Toshiba,  Japan).  Quantitative 
perfusion software (CHI-Q Laboratory, Toshiba, Japan) provides time intensity curve 
of enhancement (right window). Several perfusion parameters can be extracted after 
modelling, ie, maximum intensity, slope, area under wash-out, area under wash-in, 
time to peak, mean transit time.
A
B
C
Figure 2 In transit melanoma metastasis treated by isolated limb perfusion in a good 
responder. Ultrasound B mode (gray scale) scanning of superficial subcutaneous 
hypoechoic nodule of the right limb. A) Before treatment, the lesion was 14.8 mm 
in size. B) At day 1 after treatment no significant morphologic change was observed 
(14.2 mm). C) At day 7, the lesion shows a significant decrease in size (8.3 mm). 
D) In the same patient, after modelling, perfusion curves expressed as linear raw 
data show an important increase in perfusion parameters at day 1 after treatment 
compared with baseline.
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enhancement with excellent spatial and temporal resolution, 
and provides time intensity curves (Figure 1).
Until recently, perfusion evaluation in dynamic contrast-
enhanced ultrasound in clinical trials was performed by 
visual assessment (from Dicom data). It soon became 
apparent that semiquantitative analysis is an important issue 
in terms of accuracy and reproducibility to evaluate early 
vascular changes and therapeutic efficiency. Time intensity 
curves expressed as native linear raw data provide several 
perfusion parameters correlated with blood flow and blood 
volume (maximum intensity, slope, time to peak, mean 
transit time, area under wash-out, area under wash-in). These 
parameters could be used for monitoring antiangiogenic 
therapies.
An animal study evaluating the early disruptive effects of 
AVE 8062 on tumor vasculature showed that perfusion param-
eters variations extracted from linear raw data were well cor-
related with microvascular density changes. These were more 
accurate than power Doppler or visual evaluation from video 
data.36,37 Likewise, in an initial clinical study involving 50 
patients with in transit melanoma metastasis and treated with 
isolated limb perfusion, quantification showed that initial 
changes (day 1 after treatment) in some perfusion parameters 
(maximum intensity, slope, wash-out area, time to peak) were 
significantly modified in responders38 (Figure 2).
Conclusion
Ultrasound is a low-cost and powerful technique for pre-
operative melanoma evaluation in terms of detection, 
characterization, metastatic risk, and monitoring of targeted 
treatments. Technologic advances in high frequency probes 
allow accurate morphologic and functional assessments. 
In particular, melanoma thickness, as measured with high 
frequency ultrasound, is currently considered as an effec-
tive and reliable criterion for preoperative planning. On the 
other hand, vascular assessment could be optimized by real-
time contrast-enhanced ultrasound which is able to provide 
quantitative perfusion parameters, such as biomarkers for 
new antiangiogenic therapy monitoring.
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